Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the ...
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus ( S. aureus ) in mechanically ventilated hospitalized patients
By Aridis Pharmaceuticals, Inc.
Published - May 31, 2023, 08:06 AM ET
Last Updated - May 06, 2024, 12:54 PM EDT
LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus ( S. aureus ) in mechanically ventilated hospitalized patients.
Key agreements with FDA: